Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

7.1%

3 terminated/withdrawn out of 42 trials

Success Rate

91.2%

+4.7% vs industry average

Late-Stage Pipeline

17%

7 trials in Phase 3/4

Results Transparency

0%

0 of 31 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 1
13(44.8%)
Phase 2
6(20.7%)
Phase 4
5(17.2%)
N/A
3(10.3%)
Phase 3
2(6.9%)
29Total
Phase 1(13)
Phase 2(6)
Phase 4(5)
N/A(3)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (42)

Showing 20 of 42 trials
NCT07474285Enrolling By Invitation

Cenobamate Efficacy in Individuals With Autoimmune Epilepsy

Role: collaborator

NCT07224581Phase 3Recruiting

Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder

Role: collaborator

NCT07377682Recruiting

Real-world Clinical Response to Trazodone in Italy, Poland, and Romania

Role: lead

NCT06922175Recruiting

REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization

Role: lead

NCT07199543Phase 1Completed

Palatability Study of Five Formulations of Benzydamine HCl Lozenges

Role: lead

NCT06716801Recruiting

Real-world Clinical Response to Cenobamate Early add-on in France, Germany and Spain

Role: lead

NCT05867160Active Not Recruiting

Adjunctive Anti-seizure Medication (ASM) Real World Evidence (RWE) Study

Role: lead

NCT06650631Not ApplicableRecruiting

The Effectiveness of Heat Treatment on Knee Pain in Patients With Osteoarthritis - an International, Multicenter Clinical Investigation

Role: lead

NCT05859854Active Not Recruiting

Cenobamate in Adults With Focal-Onset Seizures

Role: lead

NCT06773767Phase 1Completed

Bioavailability of Trazodone Hydrochloride (New Polymer) vs. Trazodone Hydrochloride Contramid® at Steady-state.

Role: lead

NCT05204667Phase 4Terminated

Different Dosage Regimens of Methocarbamol/Paracetamol in Acute Non-specific Low Back Pain. MioPain Study

Role: lead

NCT06527885Completed

Lurasidone Non-Interventional Study in Schizophrenia Patients

Role: lead

NCT06358586Not ApplicableCompleted

New Paediatric Formulation of Tachipirina®

Role: lead

NCT06111118Not ApplicableCompleted

The Effectiveness of Sustained Heat Treatment on Delayed-Onset Muscle Soreness (DOMS)

Role: lead

NCT05747001Completed

This is a Retrospective Study on the Use of CENOBAMATE as Adjunctive Treatment in Patients Suffering From Epilepsy in Early Access Program in Germany, France and UK

Role: lead

NCT04312503Completed

Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"

Role: lead

NCT05222724Phase 4Completed

Efficacy of the Combination of Ibuprofen and Paracetamol in Acute Non-specific Low Back Pain

Role: lead

NCT05055726Phase 4Completed

Benzydamine Oromucosal Solution in Oral Mucositis (BOOM)

Role: lead

NCT04959799Completed

Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA)

Role: lead

NCT04295941Completed

Long-term Study With Trazodone Once-a-Day

Role: lead